Nab-paclitaxel /m^2 is named as a drug or biological intervention in 2 clinical trials in our USA and UK trial registers, 1 of which is recruiting. The lead sponsor is Corcept Therapeutics. Registered phases: Phase 3 and Phase 2. Conditions studied include Peritoneal Neoplasms; Ovarian Neoplasm; Fallopian Tube Neoplasms.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06906341 | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms |
Phase 2 | Recruiting |
| NCT05257408 | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ClinicalTrials.gov ↗) Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms |
Phase 3 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Peritoneal Neoplasms | 2 |
| Ovarian Neoplasm | 1 |
| Fallopian Tube Neoplasms | 1 |
| Ovarian Cancer | 1 |
| Fallopian Tube Cancer | 1 |
| Endometrial Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| Corcept Therapeutics | 2 |
| Register | Nab-paclitaxel /m^2 trials |
|---|---|
| Clinical trials in USA | 2 |
| Clinical trials in UK | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Nab-paclitaxel /m^2 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nab-paclitaxel /m^2 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.